trending Market Intelligence /marketintelligence/en/news-insights/trending/co4ftzpdgatp6g2-taaata2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants priority review for Tesaro's cancer drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


US FDA grants priority review for Tesaro's cancer drug

The U.S. FDA granted a priority review to Tesaro Inc.'s new drug application for niraparib, a poly ADP-ribose polymerase inhibitor.

Niraparib is being evaluated as a potential new treatment option for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy.

The application for niraparib is supported by a phase 3 study that showed that niraparib treatment significantly prolonged progression-free survival compared to placebo.

The FDA set a target action date under the Prescription Drug User Fee Act of June 30, 2017, and is not planning to hold an advisory committee meeting to discuss the application.

An expanded access program for niraparib in the U.S. is planned to open in January 2017.